- Join Paid Clinical Trials for Benign Prostate Hyperplasia

Paid Clinical Trials and Focus Groups


Find Paid Clinical Trials

Paid Clinical Trials - : Benign Prostate (BPH)

Top of Directory » All Categories » by Illness » Benign Prostate (BPH)



  • Study on Duration of Bone Turnover Suppression Following Zoledronic Acid in Prostate Cancer

    Condition:   Prostate Cancer
    Intervention:  
    Sponsors:   University Health Network, Toronto;   Princess Margaret Hospital, Canada
    Not yet recruiting - verified November 2009
  • Studying Genes, Environment, and Prostate Cancer Risk in Patients With or Without Prostate Cancer and Their First-Degree Relatives

    Condition:   Prostate Cancer
    Interventions:   Genetic: DNA analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: medical chart review;   Other: questionnaire administration;   Procedure: evaluation of cancer risk factors;   Procedure: study of high risk factors
    Sponsor:   Veterans Affairs Medical Center - Portland
    Recruiting - verified November 2009
  • Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer

    Condition:   Metastatic Prostate Cancer
    Interventions:   Dietary Supplement: phytochemical;   Drug: Docetaxel
    Sponsor:   Centre Jean Perrin
    Recruiting - verified November 2009
  • Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy

    Condition:   Prostate Cancer
    Interventions:   Dietary Supplement: tomato-soy juice;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: therapeutic conventional surgery
    Sponsors:   Arthur G. James Cancer Hospital & Richard J. Solove Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Feasibility of Using SPECT/CT Imaging to Map Lymphatic Drainage Patterns in Prostate Cancer Patients

    Condition:   Prostate Cancer
    Intervention:   Other: SPECT-CT imaging
    Sponsor:   University of California, San Francisco
    Recruiting - verified November 2009
  • Testosterone-Guided Schedule of Androgen Deprivation Therapy (ADT) as an Alternative to A Fixed Schedule In Management Of Prostate Cancer

    Condition:   Prostate Cancer
    Intervention:  
    Sponsor:   University Health Network, Toronto
    Not yet recruiting - verified October 2009
  • Multifunctional Magnetic Resonance (MR) for Radiotherapy Planning in Prostate Cancer

    Condition:   Prostate Cancer
    Interventions:   Other: Imaging Investigations (not radiation);   Other: Other
    Sponsors:   Royal Marsden NHS Foundation Trust;   Institute of Cancer Research, United Kingdom
    Recruiting - verified November 2009
  • Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)

    Condition:   Prostate Cancer
    Interventions:   Drug: Zoledronic acid;   Drug: Placebo
    Sponsor:   Austin Health
    Not yet recruiting - verified November 2009
  • Guided Biopsy for Mapping Prostate Cancer

    Condition:   Prostate Cancer
    Intervention:   Procedure: Prostatectomy
    Sponsor:   Roswell Park Cancer Institute
    Not yet recruiting - verified November 2009
  • A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)

    Condition:   Prostatic Hyperplasia
    Intervention:   Drug: Doxazosin mesylate GITS
    Sponsor:   Pfizer
    Not yet recruiting - verified October 2009
  • Genetic Investigation of Solid Tumors Cohort

    Conditions:   Prostate Cancer;   Colon Cancer
    Intervention:  
    Sponsor:   Scripps Translational Science Institute
    Recruiting - verified October 2009
  • Open-Label Extension Study of L-O-M® MCS in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)

    Conditions:   Lower Urinary Tract Symptoms;   Benign Prostatic Hyperplasia
    Intervention:   Drug: L-O-M MCS
    Sponsor:   Health Ever Bio-Tech Co., Ltd.
    Not yet recruiting - verified October 2009
  • L-O-M® MCS in the Treatment of Lower Urinary Tract Symptoms

    Conditions:   Lower Urinary Tract Symptoms;   Benign Prostatic Hyperplasia
    Interventions:   Drug: L-O-M® MCS 15 mg/day;   Drug: L-O-M® MCS 30 mg/day;   Drug: Placebo
    Sponsor:   Health Ever Bio-Tech Co., Ltd.
    Not yet recruiting - verified October 2009
  • A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer

    Conditions:   Prostate Cancer;   Metastasis
    Intervention:   Drug: ZD4054
    Sponsors:   Aarhus University Hospital;   Copenhagen Trial Unit, Center for Clinical Intervention Research
    Not yet recruiting - verified October 2009
  • Open-Label Extension Study of L-O-M® MCS in the Treatment of Lower Urinary Tract Symptoms

    Conditions:   Lower Urinary Tract Symptoms;   Benign Prostatic Hyperplasia
    Intervention:   Drug: L-O-M MCS
    Sponsor:   Health Ever Bio-Tech Co., Ltd.
    Not yet recruiting - verified October 2009
  • Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Simulator

    Conditions:   Prostatic Neoplasms;   Cancer of Prostate;   Prostate Cancer;   Prostate Neoplasms
    Interventions:   Procedure: Laparoscopic Radical Prostatectomy (without a simulator) - no intervention;   Procedure: Laparoscopic Radical Prostatectomy (with a simulator)
    Sponsor:   Assistance Publique - Hôpitaux de Paris
    Not yet recruiting - verified October 2009
  • Efficacy and Safety of L-O-M® MCS in the Treatment of Lower Urinary Tract Symptoms

    Conditions:   Lower Urinary Tract Symptoms;   Benign Prostatic Hyperplasia
    Interventions:   Drug: L-O-M MCS;   Drug: Placebo
    Sponsor:   Health Ever Bio-Tech Co., Ltd.
    Not yet recruiting - verified October 2009
  • Safety Study of PLX108-01 in Patients With Solid Tumors

    Condition:   Solid Tumors
    Intervention:   Drug: PLX3397
    Sponsor:   Plexxikon
    Recruiting - verified October 2009
  • L-O-M® MCS Pharmacokinetics of Lycopene in Healthy Volunteers

    Condition:   Healthy
    Intervention:   Drug: L-O-M® MCS soft-gel capsule
    Sponsor:   Health Ever Bio-Tech Co., Ltd.
    Not yet recruiting - verified October 2009
  • Prostate Biopsy Antisepsis

    Condition:   Infective Complications Post-transrectal Prostate Biopsy
    Intervention:   Drug: Povidone-iodine
    Sponsor:   University of British Columbia
    Recruiting - verified November 2009
  • Eligard Observational Registry for Patients With Prostate Cancer

    Condition:   Cancer of the Prostate
    Intervention:  
    Sponsors:   CMX Research;   Sanofi-Aventis
    Recruiting - verified October 2009
  • Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

    Condition:   Castrate-Resistant Prostate Cancer
    Intervention:   Drug: Lenalidomide (CC-5013) 10mg, 15mg, 20mg, 25mg and their respective matching placebo capsules for oral administration
    Sponsor:   Celgene Corporation
    Recruiting - verified November 2009
  • A Study of the Safety and Efficacy of Single-agent CNTO 888 (an Anti CC-Chemokine Ligand 2 [CCL2]) in Patients With Metastatic Prostate Cancer

    Condition:   Prostate Cancer
    Intervention:   Drug: CNTO888
    Sponsor:   Centocor, Inc.
    Recruiting - verified November 2009
  • Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers

    Condition:   Prostate Cancer
    Interventions:   Other: high performance liquid chromatography;   Other: laboratory biomarker analysis;   Other: mass spectrometry
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

    Condition:   Castration-Resistant Prostate Cancer
    Interventions:   Drug: MDV3100;   Drug: Placebo
    Sponsor:   Medivation, Inc.
    Recruiting - verified November 2009
  • Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

    Conditions:   Colorectal Neoplasms;   Lung Neoplasms;   Breast Neoplasms;   Prostatic Neoplasms;   Sarcoma
    Interventions:   Drug: figitumumab;   Drug: pegvisomant
    Sponsor:   Pfizer
    Not yet recruiting - verified November 2009
  • A Study of Tadalafil in Men With Benign Prostatic Hyperplasia

    Condition:   Benign Prostatic Hyperplasia
    Interventions:   Drug: Tadalafil;   Drug: Placebo tablet;   Drug: Tamsulosin;   Drug: Placebo capsule
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009
  • Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

    Condition:   Prostate Cancer
    Interventions:   Radiation: Proton Therapy;   Radiation: Photon, Proton and Hormonal Therapy;   Radiation: Proton Therapy;   Radiation: Photon, Proton and Hormonal Therapy
    Sponsor:   University of Florida
    Recruiting - verified October 2009
  • ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

    Condition:   Prostate Cancer
    Interventions:   Drug: TOK-001;   Drug: TOK-001;   Drug: TOK-001
    Sponsor:   Tokai Pharmaceuticals
    Recruiting - verified November 2009
  • Radiation Therapy With or Without Hormone Therapy in Treating Patients Who Have Undergone Surgery For Stage I, Stage II, or Stage III Prostate Cancer

    Condition:   Prostate Cancer
    Interventions:   Drug: antiandrogen therapy;   Drug: leuprolide acetate;   Radiation: 3-dimensional conformal radiation therapy
    Sponsor:   European Organization for Research and Treatment of Cancer
    Recruiting - verified November 2009
  • Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

    Condition:   Benign Prostatic Hyperplasia (BPH)
    Interventions:   Drug: NX-1207;   Drug: Placebo
    Sponsor:   Nymox Corporation
    Recruiting - verified October 2009
  • Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

    Conditions:   Bladder Cancer;   Prostate Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
    Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: placebo administration
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

    Condition:   Prostate Cancer
    Interventions:   Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin;   Drug: leuprolide acetate;   Drug: triptorelin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Study of XL184 in Adults With Advanced Malignancies

    Conditions:   Solid Tumors;   Cancer
    Interventions:   Drug: XL184;   Drug: Placebo;   Drug: XL184
    Sponsor:   Exelixis
    Recruiting - verified October 2009
  • Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy

    Conditions:   Prostate Cancer;   Sexual Dysfunction and Infertility
    Interventions:   Drug: tadalafil;   Other: placebo
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • Modifications to Radical Prostatectomy: Feasibility Study

    Condition:   Prostate Cancer
    Interventions:   Procedure: radical prostatectomy with urethral irrigation but no fascial suturing, QOL forms;   Procedure: radical prostatectomy with fascial suturing but no urethral irrigation, QOL forms;   Procedure: radical prostatectomy with both urethral irrigation and fascial suturing, QOL forms;   Procedure: radical prostatectomy with neither urethral irrigation nor fascial suturing, QOL forms
    Sponsor:   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified November 2009
  • A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

    Conditions:   Cancer;   Cataract;   Low Bone Mineral Density;   Osteopenia;   Osteoporosis;   Prostate Cancer
    Interventions:   Biological: Denosumab;   Biological: Placebo
    Sponsor:   Amgen
    Not yet recruiting - verified November 2009
  • Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer

    Condition:   Prostate Cancer
    Intervention:   Drug: (C-11 Acetate)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...

    Conditions:   Prostate Cancer;   Breast Cancer;   Lung Cancer;   Colorectal Cancer;   Head and Neck Cancer
    Interventions:   Biological: GI-6207 [Recombinant Saccharomyces Cerevisia;   Drug: (Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2009
  • A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade(Registered Trademark)), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroi...

    Conditions:   Breast Cancer;   Colon Cancer;   Prostate Cancer;   Lung Cancer;   Adrenal Cancer;   Renal Cancer;   Gastric Cancer;   Ovarian Cancer;   Cervical Cancer;   Thyroid Cancer;   Sarcoma
    Interventions:   Drug: VELCADE, PS-341 (Bortezomib, NSC #681239);   Drug: ZACTIMA (Vandetanib) (ZD6474)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2009
  • Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

    Condition:   Benign Prostatic Hyperplasia
    Interventions:   Drug: NX-1207;   Drug: Placebo
    Sponsor:   Nymox Corporation
    Recruiting - verified October 2009
  • Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer

    Conditions:   Prostate Cancer;   Adenocarcinoma
    Intervention:   Radiation: Hypofractionated, image-guided, intensity-modulated external beam radiation
    Sponsor:   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified November 2009
  • Changes in DNA After Radiation Therapy in Patients With Prostate Cancer

    Condition:   Prostate Cancer
    Interventions:   Genetic: microarray analysis;   Other: laboratory biomarker analysis
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified October 2009
  • Open Label Study of Sipuleucel-T

    Condition:   Prostate Cancer
    Intervention:   Drug: Sipuleucel-T
    Sponsor:   Dendreon
    Recruiting - verified November 2009
  • Interactive Spaced Education to Optimize Hypertension Management

    Condition:   Hypertension
    Intervention:   Other: Interactive Spaced Education (ISE) --- online education
    Sponsor:   Department of Veterans Affairs
    Not yet recruiting - verified November 2009
  • A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia

    Condition:   Benign Prostatic Hyperplasia
    Interventions:   Biological: Botulinum Toxin Type A;   Biological: Placebo (saline)
    Sponsor:   Allergan
    Recruiting - verified November 2009
  • A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy

    Condition:   Prostate Cancer
    Interventions:   Drug: Itraconazole 200 mg;   Drug: Itraconazole 300mg
    Sponsors:   Johns Hopkins University;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified October 2009
  • Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation

    Condition:   Prostate Cancer
    Interventions:   Dietary Supplement: cholecalciferol;   Other: placebo
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified October 2009
  • Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

    Condition:   Prostate Cancer
    Interventions:   Drug: abiraterone acetate plus prednisone/prednisolone;   Drug: placebo plus prednisone/prednisolone
    Sponsor:   Cougar Biotechnology, Inc.
    Recruiting - verified November 2009
  • Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

    Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:   Procedure: assessment of therapy complications
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
    • Menu
    Find Paid Clinical Trials